Understanding OCUL’s financial ratios: A beginner’s guide

In the current trading session, Ocular Therapeutix Inc’s (OCUL) stock is trading at the price of $9.47, a gain of 13.11%% over last night’s close. So, the stock is trading at a price that is -19.60% less than its 52-week high of $11.77 and 63.65% better than its 52-week low of $5.78. Based on the past 30-day period, the stock price is -2.34% below the high and +33.97% above the low.

The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, OCUL’s SMA-200 is $8.45.

It is also essential to consider OCUL stock ratios like the price-to-sales ratio, which is 25.28 for the last year.OCUL’s price to book ratio for the most recent quarter was 5.67, resulting in an 4.31 price to cash per share for the period.

How does Ocular Therapeutix Inc (OCUL) stock rate among analysts? Buy, sell, or hold?

The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 12 brokerage firms that recommend the stock as a Strong Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 4.83 in simple terms.

Ocular Therapeutix Inc (OCUL): Earnings History

Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 7 different analysts, who are expecting earnings to fall in between the range of -0.28 and -0.38 with an average Earnings Estimate of -0.35 which is in contrast with the last year earnings estimate of -0.24 and also replicates -45.83% growth rate year over year.

Ocular Therapeutix Inc (NASDAQ: OCUL) Ownership Details

I will give a breakdown of the key shareholders in Ocular Therapeutix Inc (OCUL). Recent figures show that the company’s insiders hold 3.59% of shares. A total of 256 institutional investors hold shares in the company, making 87.01% of its stock and 90.25% of its float.

Mar 31, 2025 , it was reported that the Company’s largest institutional holder is Deep Track Capital, Lp holding total of 14.29 shares that make 8.97% of the company’s total number of shares and are currently priced at 134.25 million.

The securities firm Summer Road LLC holds 13.88 shares of OCUL, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 8.71% , and the holding percentage of shares is valued at 130.34 million.

An overview of Ocular Therapeutix Inc’s technicals

In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Ocular Therapeutix Inc (OCUL) traded 2,582,712 shares per day, with a moving average of $8.43 and price change of +1.89. With the moving average of $7.91 and a price change of +2.78, about 1,974,369 shares changed hands on average over the past 50 days. Finally, OCUL’s 100-day average volume is 1,759,281 shares, alongside a moving average of $7.61 and a price change of +1.35.

Hot this week

What to expect from EXK’s earnings report this quarter?

In the current trading session, Endeavour Silver Corp's (EXK)...

Predicting Futu Holdings Ltd ADR’s (FUTU) earnings for the current quarter

Futu Holdings Ltd ADR (FUTU)'s stock is trading at...

NAK’s Q2 earnings predictions: What the experts say

Northern Dynasty Minerals Ltd (NAK)'s stock has witnessed a...

How will Leap Therapeutics Inc’s (LPTX) earnings compare to estimates this quarter?

Currently, Leap Therapeutics Inc's (LPTX) stock is trading at...

ENVX’s Q2 earnings estimates: What investors need to know

In the current trading session, Enovix Corporation's (ENVX) stock...

Topics

What to expect from EXK’s earnings report this quarter?

In the current trading session, Endeavour Silver Corp's (EXK)...

Predicting Futu Holdings Ltd ADR’s (FUTU) earnings for the current quarter

Futu Holdings Ltd ADR (FUTU)'s stock is trading at...

NAK’s Q2 earnings predictions: What the experts say

Northern Dynasty Minerals Ltd (NAK)'s stock has witnessed a...

How will Leap Therapeutics Inc’s (LPTX) earnings compare to estimates this quarter?

Currently, Leap Therapeutics Inc's (LPTX) stock is trading at...

ENVX’s Q2 earnings estimates: What investors need to know

In the current trading session, Enovix Corporation's (ENVX) stock...

Can Webull Corp (BULL) meet market expectations this quarter?

Webull Corp (BULL)'s stock is trading at $10.87 at...

LESL’s earnings forecast for the current quarter

Leslies Inc (LESL)'s stock has witnessed a price hike...

Breaking down LAB’s current quarter earnings estimates

Currently, Standard BioTools Inc's (LAB) stock is trading at...
spot_img

Related Articles

Popular Categories

spot_imgspot_img
US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.